Establishing Good Practices for Exposure–Response Analysis of Clinical Endpoints in Drug Development

@inproceedings{Overgaard2015EstablishingGP,
  title={Establishing Good Practices for Exposure–Response Analysis of Clinical Endpoints in Drug Development},
  author={RV Overgaard and S H Ingwersen and CW Torn\oe},
  booktitle={CPT: pharmacometrics & systems pharmacology},
  year={2015}
}
This tutorial aims at promoting good practices for exposure-response (E-R) analyses of clinical endpoints in drug development. The focus is on practical aspects of E-R analyses to assist modeling scientists with a process of performing such analyses in a consistent manner across individuals and projects and tailored to typical clinical drug development decisions. This includes general considerations for planning, conducting, and visualizing E-R analyses, and how these are linked to key… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 33 references

PK in late phase trials

Y. Wang
Ann . Rheum . Dis . • 2015

the concentration-effect curve

Pouw, M. F. et al. Key findings towards optimising adalimum treatment
Ann. Rheum. Dis. 74, 513–518 • 2015
View 1 Excerpt

Exposure-response—does it have more to offer MBDD and how to get us there

R. V. Overgaard
American Conference of Pharmacometrics, Las Vegas • 2014
View 1 Excerpt

A Time to Event Tutorial for Pharmacometricians

CPT: pharmacometrics & systems pharmacology • 2013

Similar Papers

Loading similar papers…